세계의 체외분비 기능부전(EPI) 시장 보고서(2025년)

Exocrine Pancreatic Insufficiency Global Market Report 2025

US $ 4,490 ￦ 6,156,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,898,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,640,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

체외분비 기능부전 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 6.7%로 성장할 전망이며, 35억 8,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 의식 향상 및 스크리닝의 지속적인 증가, 노인 인구 확대, 만성 질환 발생률의 상승, 헬스케어에 대한 환자 접근성 개선, 소화기계 건강에 관한 연구 개발에 기인할 것으로 보입니다. 예측 기간 주요 동향에는 원격의료 및 디지털 헬스 솔루션, 공동연구 이니셔티브, 소아 EPI에 대한 주력, 규제 진전 및 패스트트랙 지정, 신흥국에서의 시장 확대, 헬스케어 인프라의 진보 등이 포함됩니다.

만성질환의 유병률 증가는 향후 체외분비 기능부전 시장의 성장을 이끌 것으로 예상됩니다. 만성질환은 보통 3개월 이상 지속되는 장기적인 질환입니다. 이런 상태가 지속되면 체외분비 기능부전과 같은 2차적 합병증이 발생할 위험도 높아지기 때문에 치료나 관리를 통한 만성질환의 더 나은 관리가 촉진돼 이 환자의 수명이 연장될 수 있습니다. 예를 들어 2023년 9월 스위스에 본부를 둔 유엔 전문기구인 세계보건기구(WHO)는 전 세계적으로 연간 4,100만 명이 사망하였고, 그 74%가 비감염성질환(NCDs) 또는 만성질환에 기인한다고 보고했습니다. 그 결과 만성질환의 증가는 체외분비 기능부전 시장의 성장을 가속화시킬 것으로 보입니다.

당뇨병 환자 증가는 체외분비 기능부전 시장의 성장을 가속할 것으로 예상됩니다. 당뇨병은 체내에서 인슐린의 생산 및 이용이 불충분한 것을 특징으로 하는 만성적인 건강 상태이며, 혈류에 과도한 혈당이 축적됩니다. 췌장 효소 보충 치료(PERT)는 체외분비 기능부전(EPI)에 충분한 소화 효소를 공급하고 체내 인슐린 수준을 유지하는데 필수적입니다. 예를 들어 2023년 6월에 Institute for Health Metrics and Evaluation이 발표한 보고서에 따르면 세계 당뇨병 환자는 2022년 5억 2900만 명에서 2050년에는 13억 명에 이를 것으로 예측되고 있습니다. 따라서 당뇨병 유병률 증가는 체외분비 기능부전 시장의 성장을 촉진할 것으로 예상됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

• 세계의 체외분비 기능부전 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 체외분비 기능부전 시장 : 성장률 분석
• 세계의 체외분비 기능부전 시장 실적 : 규모 및 성장(2019-2024년)
• 세계의 체외분비 기능부전 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
• 세계의 체외분비 기능부전 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 체외분비 기능부전 시장 : 치료별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 영양 관리
• 췌장효소 보충요법(PERT)
• 기타 치료법
• 세계의 체외분비 기능부전 시장 : 진단별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 화상 검사
• 컴퓨터 단층 촬영(CT) 스캔
• 복부 초음파 검사
• 세크레틴 췌장 기능 검사
• 대변지방검사
• 편중 엘라스타제 검사(FE-1)
• 기타 유형
• 세계의 체외분비 기능부전 시장 : 증상별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 복통
• 변비
• 설사
• 지방편
• 체중 감량
• 기타 증상
• 세계의 체외분비 기능부전 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 약국
• 소매 약국
• 온라인 약국
• 기타 유통 채널
• 세계의 체외분비 기능부전 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 전문 클리닉
• 홈케어
• 세계의 체외분비 기능부전 시장 : 영양 관리별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 식생활의 변경
• 영양보조식품
• 세계의 체외분비 기능부전 시장 : 췌장 효소 보충 치료(PERT)별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 장용성 캡슐
• 비장용성 캡슐
• 분말 제형
• 세계의 체외분비 기능부전 시장 : 기타 치료법별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 의약품
• 외과적 개입
• 지지요법

제7장 지역별 및 국가별 분석

• 세계의 체외분비 기능부전 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 체외분비 기능부전 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

• 체외분비 기능부전 시장 : 경쟁 구도
• 체외분비 기능부전 시장 : 기업 프로파일
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • F. Hoffmann-La Roche AG 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Janssen Pharmaceuticals Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • AbbVie Inc. 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Bayer AG
• Novartis AG
• Sanofi SA
• AstraZeneca plc
• Medtronic plc
• Eli Lilly and Company
• Gilead Sciences Inc.
• Nestle Health Science SA
• Allergan plc
• Chiesi Farmaceutici SpA
• Wockhardt Ltd.
• Amryt Pharma Plc
• Codexis Inc.
• Nordmark Arzneimittel GmbH & Co. KG
• Aimmune Therapeutics Inc

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

• 체외분비 기능부전 시장 : 새로운 기회를 제공하는 국가(2029년)
• 체외분비 기능부전 시장 : 새로운 기회를 제공하는 부문(2029년)
• 체외분비 기능부전 시장 : 성장 전략(2029년)
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

AJY

영문 목차

영문목차

Exocrine pancreatic insufficiency (EPI) is a medical condition characterized by the insufficient production or release of digestive enzymes by the pancreas into the small intestine. These enzymes are crucial for the proper digestion and absorption of nutrients from ingested food. Exocrine pancreatic insufficiency can result in malnutrition and various digestive symptoms, such as diarrhea, abdominal pain, bloating, and weight loss.

The primary types of treatments for exocrine pancreatic insufficiency include nutritional management, pancreatic enzyme replacement therapy (PERT), and other interventions. Nutritional management involves planning and implementing dietary strategies to optimize an individual's nutritional status, supporting overall health and well-being. This approach is essential in the comprehensive care of individuals with exocrine pancreatic insufficiency (EPI), diagnosed through imaging tests such as Computed Tomography (CT) Scan, Abdominal Ultrasound, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-1), and others. These diagnostic tests help identify symptoms such as abdominal pain, constipation, diarrhea, fatty stool, and weight loss. The drugs used for treating exocrine pancreatic insufficiency are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other outlets. These medications are utilized by end users such as hospitals, specialty clinics, and individuals receiving care at home.

The exocrine pancreatic insufficiency market research report is one of a series of new reports from The Business Research Company that provides exocrine pancreatic insufficiency market statistics, including exocrine pancreatic insufficiency industry global market size, regional shares, competitors with a exocrine pancreatic insufficiency market share, detailed exocrine pancreatic insufficiency market segments, market trends and opportunities, and any further data you may need to thrive in the exocrine pancreatic insufficiency industry. This exocrine pancreatic insufficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future- scenario of the industry.

The exocrine pancreatic insufficiency market size has grown strongly in recent years. It will grow from $2.59 billion in 2024 to $2.76 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to increased awareness and diagnosis, growing prevalence of digestive disorders, aging population, and pancreatic function decline, rise in gastrointestinal surgeries.

The exocrine pancreatic insufficiency market size is expected to see strong growth in the next few years. It will grow to $3.58 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to continued increase in awareness and screening, expanding geriatric population, rising incidence of chronic diseases, improvements in patient access to healthcare, research and development in digestive health. Major trends in the forecast period include telehealth and digital health solutions, collaborative research initiatives, focus on pediatric epi, regulatory advances and fast-track designations, market expansion in emerging economies, advancements in healthcare infrastructure.

The increasing prevalence of chronic diseases is expected to drive the growth of the exocrine pancreatic insufficiency market in the future. Chronic diseases are long-term conditions that last for extended periods, typically over three months. The ongoing presence of these conditions can also heighten the risk of developing secondary complications, such as exocrine pancreatic insufficiency, which in turn promotes better management of chronic diseases through medical treatments and therapies, potentially extending the lives of affected individuals. For example, in September 2023, the World Health Organization (WHO), a specialized agency of the United Nations based in Switzerland, reported that 41 million deaths occur annually, with 74% of these attributed to non-communicable diseases (NCDs) or chronic diseases worldwide. Consequently, the rise in chronic diseases will accelerate the growth of the exocrine pancreatic insufficiency market.

The escalating cases of diabetes are expected to fuel the growth of the exocrine pancreatic insufficiency market. Diabetes, a chronic health condition characterized by inadequate insulin production or utilization by the body, leads to an accumulation of excessive blood sugar in the bloodstream. Pancreatic enzyme replacement treatment (PERT) becomes essential to supply adequate digestive enzymes for exocrine pancreatic insufficiency (EPI) and maintain the body's insulin levels. For instance, a report from the Institute for Health Metrics and Evaluation in June 2023 projected global diabetes cases to reach 1.3 billion by 2050, up from 529 million in 2022. Therefore, the increasing prevalence of diabetes is expected to drive the growth of the exocrine pancreatic insufficiency market.

Leading companies in the exocrine pancreatic insufficiency market are focusing on establishing patient advocacy initiatives, such as offering comprehensive nutritional guidance and support. These efforts aim to raise awareness, educate, and improve the management of the condition for those affected. Comprehensive nutritional guidance is an all-encompassing approach that customizes dietary recommendations according to individual needs, health status, and lifestyle. It emphasizes education, meal planning, and sustainable practices to promote overall well-being. For example, in June 2024, Nestle Health Science, a Switzerland-based nutrition company, launched a GLP-1 nutrition support platform. This platform provides personalized nutritional resources and expert advice for individuals using GLP-1 medications, focusing on muscle preservation, gut health, and general wellness. Its goal is to empower users on their weight management journey by addressing specific dietary needs and building community support.

In December 2023, Codexis, a US-based pharmaceutical company, acquired a division of Nestle Health Science for an undisclosed amount. Through this acquisition, Codexis aims to monetize its asset CDX-7108, concentrate on core projects, and leverage Nestle's expertise to expedite development while maintaining economic interest. Nestle Health Science, a Switzerland-based science-driven nutrition company, offers specialized nutritional products to aid individuals with exocrine pancreatic insufficiency by enhancing digestion and nutrient absorption.

Major companies operating in the exocrine pancreatic insufficiency market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Nestle Health Science S.A., Allergan PLC, Chiesi Farmaceutici S.p.A., Wockhardt Ltd., Amryt Pharma PLC, Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, Aimmune Therapeutics Inc., Digestive Care Inc., Enzymedica Inc., Vivus Inc., Alcresta Therapeutics Inc., Cilian AG, Perseo Pharma AG, Enzyme Development Corporation, First Wave BioPharma Inc., Synspira Therapeutics

North America was the largest region in the exocrine pancreatic insufficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exocrine pancreatic insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the exocrine pancreatic insufficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The exocrine pancreatic insufficiency market consists of revenues earned by entities by providing enzyme replacement therapy, nutritional counseling, monitoring, managing underlying conditions, lifestyle modifications, and gastroenterology consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. The exocrine pancreatic insufficiency market also includes sales of Creon, zenpep, pancreaze, ultresa, and viokace. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Exocrine Pancreatic Insufficiency Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on exocrine pancreatic insufficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for exocrine pancreatic insufficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The exocrine pancreatic insufficiency market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Nutritional Management; Pancreatic Enzyme Replacement Therapy (PERT); Other Treatments
• 2) By Diagnosis: Imaging Tests; Computed Tomography (CT) Scan; Abdominal Ultrasound; Secretin Pancreatic Function Test; Fecal Fat Test; Fecal Elastase Test (FE-1); Other Types
• 3) By Symptoms: Abdominal Pain; Constipation; Diarrhea; Fatty Stools; Weight Loss; Other Symptoms
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 5) By End Users: Hospitals; Specialty Clinics; Homecare
• Subsegments:
• 1) By Nutritional Management: Dietary Modifications; Nutritional Supplements
• 2) By Pancreatic Enzyme Replacement Therapy (PERT): Enteric-Coated Capsules; Non-Enteric-Coated Capsules; Powder Formulations
• 3) By Other Treatments: Medications; Surgical Interventions; Supportive Therapies
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Janssen Pharmaceuticals Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Exocrine Pancreatic Insufficiency Market Characteristics

3. Exocrine Pancreatic Insufficiency Market Trends And Strategies

4. Exocrine Pancreatic Insufficiency Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Exocrine Pancreatic Insufficiency Growth Analysis And Strategic Analysis Framework

• 5.1. Global Exocrine Pancreatic Insufficiency PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Exocrine Pancreatic Insufficiency Market Growth Rate Analysis
• 5.4. Global Exocrine Pancreatic Insufficiency Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Exocrine Pancreatic Insufficiency Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Exocrine Pancreatic Insufficiency Total Addressable Market (TAM)

6. Exocrine Pancreatic Insufficiency Market Segmentation

• 6.1. Global Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nutritional Management
• Pancreatic Enzyme Replacement Therapy (PERT)
• Other Treatments
• 6.2. Global Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging Tests
• Computed Tomography (CT) Scan
• Abdominal Ultrasound
• Secretin Pancreatic Function Test
• Fecal Fat Test
• Fecal Elastase Test (FE-1)
• Other Types
• 6.3. Global Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Abdominal Pain
• Constipation
• Diarrhea
• Fatty Stools
• Weight Loss
• Other Symptoms
• 6.4. Global Exocrine Pancreatic Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.5. Global Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• 6.6. Global Exocrine Pancreatic Insufficiency Market, Sub-Segmentation Of Nutritional Management, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dietary Modifications
• Nutritional Supplements
• 6.7. Global Exocrine Pancreatic Insufficiency Market, Sub-Segmentation Of Pancreatic Enzyme Replacement Therapy (PERT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enteric-Coated Capsules
• Non-Enteric-Coated Capsules
• Powder Formulations
• 6.8. Global Exocrine Pancreatic Insufficiency Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications
• Surgical Interventions
• Supportive Therapies

7. Exocrine Pancreatic Insufficiency Market Regional And Country Analysis

• 7.1. Global Exocrine Pancreatic Insufficiency Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Exocrine Pancreatic Insufficiency Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Exocrine Pancreatic Insufficiency Market

• 8.1. Asia-Pacific Exocrine Pancreatic Insufficiency Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Exocrine Pancreatic Insufficiency Market

• 9.1. China Exocrine Pancreatic Insufficiency Market Overview
• 9.2. China Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Exocrine Pancreatic Insufficiency Market

• 10.1. India Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Exocrine Pancreatic Insufficiency Market

• 11.1. Japan Exocrine Pancreatic Insufficiency Market Overview
• 11.2. Japan Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Exocrine Pancreatic Insufficiency Market

• 12.1. Australia Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Exocrine Pancreatic Insufficiency Market

• 13.1. Indonesia Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Exocrine Pancreatic Insufficiency Market

• 14.1. South Korea Exocrine Pancreatic Insufficiency Market Overview
• 14.2. South Korea Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Exocrine Pancreatic Insufficiency Market

• 15.1. Western Europe Exocrine Pancreatic Insufficiency Market Overview
• 15.2. Western Europe Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Exocrine Pancreatic Insufficiency Market

• 16.1. UK Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Exocrine Pancreatic Insufficiency Market

• 17.1. Germany Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Exocrine Pancreatic Insufficiency Market

• 18.1. France Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Exocrine Pancreatic Insufficiency Market

• 19.1. Italy Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Exocrine Pancreatic Insufficiency Market

• 20.1. Spain Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Exocrine Pancreatic Insufficiency Market

• 21.1. Eastern Europe Exocrine Pancreatic Insufficiency Market Overview
• 21.2. Eastern Europe Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Exocrine Pancreatic Insufficiency Market

• 22.1. Russia Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Exocrine Pancreatic Insufficiency Market

• 23.1. North America Exocrine Pancreatic Insufficiency Market Overview
• 23.2. North America Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Exocrine Pancreatic Insufficiency Market

• 24.1. USA Exocrine Pancreatic Insufficiency Market Overview
• 24.2. USA Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Exocrine Pancreatic Insufficiency Market

• 25.1. Canada Exocrine Pancreatic Insufficiency Market Overview
• 25.2. Canada Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Exocrine Pancreatic Insufficiency Market

• 26.1. South America Exocrine Pancreatic Insufficiency Market Overview
• 26.2. South America Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Exocrine Pancreatic Insufficiency Market

• 27.1. Brazil Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Exocrine Pancreatic Insufficiency Market

• 28.1. Middle East Exocrine Pancreatic Insufficiency Market Overview
• 28.2. Middle East Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Exocrine Pancreatic Insufficiency Market

• 29.1. Africa Exocrine Pancreatic Insufficiency Market Overview
• 29.2. Africa Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Exocrine Pancreatic Insufficiency Market Competitive Landscape And Company Profiles

• 30.1. Exocrine Pancreatic Insufficiency Market Competitive Landscape
• 30.2. Exocrine Pancreatic Insufficiency Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Janssen Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Exocrine Pancreatic Insufficiency Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Novartis AG
• 31.3. Sanofi S.A.
• 31.4. AstraZeneca plc
• 31.5. Medtronic plc
• 31.6. Eli Lilly and Company
• 31.7. Gilead Sciences Inc.
• 31.8. Nestle Health Science S.A.
• 31.9. Allergan plc
• 31.10. Chiesi Farmaceutici S.p.A.
• 31.11. Wockhardt Ltd.
• 31.12. Amryt Pharma Plc
• 31.13. Codexis Inc.
• 31.14. Nordmark Arzneimittel GmbH & Co. KG
• 31.15. Aimmune Therapeutics Inc

32. Global Exocrine Pancreatic Insufficiency Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Exocrine Pancreatic Insufficiency Market

34. Recent Developments In The Exocrine Pancreatic Insufficiency Market

35. Exocrine Pancreatic Insufficiency Market High Potential Countries, Segments and Strategies

• 35.1 Exocrine Pancreatic Insufficiency Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Exocrine Pancreatic Insufficiency Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Exocrine Pancreatic Insufficiency Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료